Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven ...
After pausing work on a rare cancer asset, Relay Therapeutics is passing the baton to Elevar Therapeutics. The two have ...
Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 ...
Three compounds isolated from tuberculosis’s fungal foes killed cultured cells of the bacterium that causes the disease in ...
Philips and the Mayo Clinic have launched a new research collaboration focused on applying artificial intelligence to MRI ...
Siemens Healthineers is rolling out artificial intelligence programs through its ultrasound platforms that automatically ...
Chicago’s Cour Pharmaceuticals—recently honored as one of Fierce Biotech’s 2024 Fierce 15—is bringing its immunology mission ...
Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...
Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French ...
Kinevant Sciences, a Roivant spinout designed to test an investigational monoclonal antibody, has reported that the asset ...
The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...